Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Jehan Mohammad Nazri, Katerina Oikonomopoulou, Elvin D. de Araujo, Dziyana Kraskouskaya, Patrick T. Gunning & Vinod Chandran. (2023) Histone deacetylase inhibitors as a potential new treatment for psoriatic disease and other inflammatory conditions. Critical Reviews in Clinical Laboratory Sciences 60:4, pages 300-320.
Read now
Read now
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, Maria Mannino, Ketty Peris & Andrea Chiricozzi. (2023) Investigational systemic drugs for moderate to severe plaque psoriasis: What’s new?. Expert Opinion on Investigational Drugs 32:3, pages 229-243.
Read now
Read now
Vishalakshi Viswanath, Pradnya Joshi, Prakash Lawate, Dakshata Tare, Dhiraj Dhoot, Namrata Mahadkar & Hanmant Barkate. (2022) An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India. Psoriasis: Targets and Therapy 12, pages 53-61.
Read now
Read now
Shaimaa A. Fattah, Maha A. Abdel Fattah, Noha M. Mesbah, Samy M. Saleh, Dina M. Abo-Elmatty & Eman T. Mehanna. (2022) The expression of zinc finger 804a (ZNF804a) and cyclin-dependent kinase 1 (CDK1) genes is related to the pathogenesis of rheumatoid arthritis. Archives of Physiology and Biochemistry 128:3, pages 688-693.
Read now
Read now
Hakim Ben Abdallah, Claus Johansen & Lars Iversen. (2021) Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. Psoriasis: Targets and Therapy 11, pages 83-97.
Read now
Read now
Elena Campione, Terenzio Cosio, Monia Di Prete, Caterina Lanna, Annunziata Dattola & Luca Bianchi. (2021) Experimental Pharmacological Management of Psoriasis. Journal of Experimental Pharmacology 13, pages 725-737.
Read now
Read now
Masutaka Furue, Takafumi Kadono, Gaku Tsuji & Takeshi Nakahara. (2017) Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis. Expert Opinion on Investigational Drugs 26:12, pages 1403-1408.
Read now
Read now
Ramya Vangipuram & Ali Alikhan. (2017) Apremilast for the management of moderate to severe plaque psoriasis. Expert Review of Clinical Pharmacology 10:4, pages 349-360.
Read now
Read now
A. Dattola, E. Del Duca, R. Saraceno, T. Gramiccia & L. Bianchi. (2017) Safety evaluation of apremilast for the treatment of psoriasis. Expert Opinion on Drug Safety 16:3, pages 381-385.
Read now
Read now
T. Torres, M. Romanelli & A. Chiricozzi. (2016) A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opinion on Investigational Drugs 25:7, pages 751-754.
Read now
Read now
Articles from other publishers (26)
Yu Jin, Xue Li, Changling Wei & Qiongjia Yuan. (2023) Effects of exercise-targeted hippocampal PDE-4 methylation on synaptic plasticity and spatial learning/memory impairments in D-galactose-induced aging rats. Experimental Brain Research.
Crossref
Crossref
Rui Ma, Na Song, Lveli Wang, Xi Gu, Feng Xiong, Shuqun Zhang, Jie Zhang, Weimin Yang & Zhili Zuo. (2023) Discovery of 2-(Methylcarbonylamino) thiazole as PDE4 inhibitors via virtual screening and biological evaluation. Journal of Molecular Graphics and Modelling 124, pages 108567.
Crossref
Crossref
Namrashee V. Mehta, Arundhati Abhyankar & Mariam S. Degani. (2023) Elemental exchange: Bioisosteric replacement of phosphorus by boron in drug design. European Journal of Medicinal Chemistry 260, pages 115761.
Crossref
Crossref
Hidetaka Hiyama, Naoya Arichika, Minoru Okada, Noriyuki Koyama, Tomonori Tahara & Junpei Haruta. (2023) Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis. Journal of Pharmacology and Experimental Therapeutics 386:1, pages 45-55.
Crossref
Crossref
Christine Youn, Dustin A. Dikeman, Evelyn Chang, Haiyun Liu, Sabrina J. Nolan, Martin P. Alphonse, Daniel P. Joyce, Qi Liu, James Meixiong, Xinzhong Dong, Lloyd S. Miller & Nathan K. Archer. (2022)
Crisaborole efficacy in murine models of skin inflammation and
Staphylococcus aureus
infection
. Experimental Dermatology 32:4, pages 425-435.
Crossref
Crossref
Letizia Crocetti, Giuseppe Floresta, Agostino Cilibrizzi & Maria Paola Giovannoni. (2022) An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules 27:15, pages 4964.
Crossref
Crossref
FangTing Yuan, HaiXia Ren, Wei Tan, Ying Wang & HeSheng Luo. (2022) Effect of phosphodiesterase‐4 inhibitor rolipram on colonic hypermotility in water avoidance stress rat model. Neurogastroenterology & Motility 34:7.
Crossref
Crossref
Ignatios Ikonomidis, George Pavlidis, Nikolaos Kadoglou, George Makavos, Konstantinos Katogiannis, Aikaterini Kountouri, John Thymis, Gavriella Kostelli, Irini Kapniari, Konstantinos Theodoropoulos, John Parissis, Pelagia Katsimbri, Evangelia Papadavid & Vaia Lambadiari. (2022) Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis. Pharmaceuticals 15:2, pages 172.
Crossref
Crossref
Pablo Rayff da Silva, Renan Fernandes do Espírito Santo, Camila de Oliveira Melo, Fábio Emanuel Pachú Cavalcante, Thássia Borges Costa, Yasmim Vilarim Barbosa, Yvnni M. S. de Medeiros e Silva, Natália Ferreira de Sousa, Cristiane Flora Villarreal, Ricardo Olímpio de Moura & Vanda Lucia dos Santos. (2022) The Compound (E)-2-Cyano-N,3-diphenylacrylamide (JMPR-01): A Potential Drug for Treatment of Inflammatory Diseases. Pharmaceutics 14:1, pages 188.
Crossref
Crossref
Valerio Caputo, Claudia Strafella, Terenzio Cosio, Caterina Lanna, Elena Campione, Giuseppe Novelli, Emiliano Giardina & Raffaella Cascella. (2021) Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes 12:9, pages 1398.
Crossref
Crossref
Natsuki Kubota-Ishida, Takashi Matsuhira, Chizuko Kaji, Chika Kikuchi & Yuji Tabata. (2021) Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models. European Journal of Pharmacology 906, pages 174258.
Crossref
Crossref
Jen-Chih Tseng, Yung-Chi Chang, Chun-Ming Huang, Li-Chung Hsu & Tsung-Hsien Chuang. (2021) Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis. Pharmaceutics 13:7, pages 1064.
Crossref
Crossref
Kent Sakai, Kristen M. Sanders, Darya Pavlenko, Taisa Lozada & Tasuku Akiyama. (2021) Crisaborole prevents infiltration of neutrophils to suppress itch in a mouse model of atopic dermatitis. Itch 6:2, pages e53-e53.
Crossref
Crossref
Veronika Furlan & Urban Bren. (2021) Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations. Biomolecules 11:3, pages 479.
Crossref
Crossref
Hiba Hashim Mahgoub Mohamed, Amna Bint Wahab Elrashid Mohammed Hussien & Ahmed Elsadig Mohammed Saeed. (2021) QSAR and docking studies of 3, 5-dimethylpyrazole as potent inhibitors of Phosphodiesterase-4. Journal of Drug Delivery and Therapeutics 11:1-s, pages 86-93.
Crossref
Crossref
Wei Xiong, Ling Wang, Haiyan Zhang, Xiaoqiu Tao, Xuehua Jiang, Zejuan Liu, Jiajia Zhao & Wenwen Xu. (2021) Quantitation of Apremilast in Beagle Dogs Plasma by UPLC-MS-MS and Its Application to Pharmacokinetic Studies. Journal of Analytical Methods in Chemistry 2021, pages 1-7.
Crossref
Crossref
Isabelle Karine da Costa Nunes, Everton Tenório de Souza, Italo Rossi Roseno Martins, Gisele Barbosa, Manoel Oliveira de Moraes Junior, Millena de Melo Medeiros, Sheyla Welma Duarte Silva, Tatiane Luciano Balliano, Bagnólia Araújo da Silva, Patrícia Machado Rodrigues Silva, Vinicius de Frias Carvalho, Marco Aurélio Martins & Lidia Moreira Lima. (2020) Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. European Journal of Medicinal Chemistry 204, pages 112492.
Crossref
Crossref
Maria Dalamaga, Irene Karampela & Christos S. Mantzoros. (2020) Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism 109, pages 154282.
Crossref
Crossref
Mauro Giorgi, Silvia Cardarelli, Federica Ragusa, Michele Saliola, Stefano Biagioni, Giancarlo Poiana, Fabio Naro & Mara Massimi. (2020) Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?. International Journal of Molecular Sciences 21:15, pages 5338.
Crossref
Crossref
Heng Li, Jian Li, Xianglei Zhang, Chunlan Feng, Chen Fan, Xiaoqian Yang, Rui Zhang, Fenghua Zhu, Yu Zhou, Yechun Xu, Hong Liu & Wei Tang. (2020) DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling. Biochemical Pharmacology 177, pages 113958.
Crossref
Crossref
Claire Lugnier, Alain Meyer, Samy Talha & Bernard Geny. (2020) Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?. Pharmacology & Therapeutics 208, pages 107475.
Crossref
Crossref
Heng Li, Chen Fan, Chunlan Feng, Yanwei Wu, Huimin Lu, Peilan He, Xiaoqian Yang, Fenghua Zhu, Qing Qi, Yuanzhuo Gao, Jianping Zuo & Wei Tang. (2019) Inhibition of phosphodiesterase‐4 attenuates murine ulcerative colitis through interference with mucosal immunity. British Journal of Pharmacology 176:13, pages 2209-2226.
Crossref
Crossref
Heng Li, Jianping Zuo & Wei Tang. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology 9.
Crossref
Crossref
Tiago Torres & Luis Puig. (2017) Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology 19:1, pages 23-32.
Crossref
Crossref
Muzaffar Iqbal, Essam Ezzeldin, Sara TA Al-Rashood, Faisal Imam & Khalid A Al-Rashood. (2016) Determination of apremilast in rat plasma by UPLC–MS/MS in ESI-negative mode to avoid adduct ions formation. Bioanalysis 8:14, pages 1499-1508.
Crossref
Crossref
Verena Katharina Raker, Christian Becker & Kerstin Steinbrink. (2016) The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. Frontiers in Immunology 7.
Crossref
Crossref